Duarte 1996.

Methods	Six‐week randomised, double‐blind study
Participants	Outpatients fulfilling DSM‐III‐R criteria for double depression (dysthymia and major depression), with a score of at least 16 on the Hamilton Rating Scale for Depression (HDRS). Age range: 18‐65 years Exclusion criteria: suicidal tendencies, delusional depression, severe organic disease, alcoholism, drug abuse, ongoing ECT or structured psychotherapy.
Interventions	Fluoxetine: 21 participants Moclobemide: 21 participants Fluoxetine dose: 20 mg/day Moclobemide dose: 300 mg/day Use of single benzodiazepines was allowed at discretion of the doctor
Outcomes	Primary outcomes: percentage of responders defined as decrease of at least 50% in the HDRS Secondary outcomes: endpoint score at HDRS, percentage of end of treatment Clinical Global Impression (CGI) very good and good responses
Notes	Funding: by industry
Risk of bias
Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Unclear risk	Randomised, no further information
Allocation concealment (selection bias)	Unclear risk	No information provided
Blinding (performance bias and detection bias) All outcomes	Unclear risk	Quote: "double blinding was achieved by appropriate drug packaging and formulation", no further information
Blinding of participants and personnel (performance bias) All outcomes	Unclear risk	Quote: "double blinding was achieved by appropriate drug packaging and formulation", no further information
Blinding of outcome assessment (detection bias) All outcomes	Unclear risk	Quote: "double blinding was achieved by appropriate drug packaging and formulation", no further information
Incomplete outcome data (attrition bias) All outcomes	High risk	Scores reported without denominators. Mean scores and standard deviations reported only in figure and they were not clear
Selective reporting (reporting bias)	Unclear risk	No vital signs and side effects reported. Quote: "no clinically significant changes in vitals signs were recorded"
Other bias	High risk	The last author's affiliation was Hoffmann–La Roche Ltd, and this company produces moclobemide